Sanofi Gen­zyme re­treats from its Parkin­son’s deal with gene ther­a­py up­start Voy­ager, part of an $845M pact

Voy­ager $VY­GR plans to launch a piv­otal study of its lead­ing gene ther­a­py for Parkin­son’s dis­ease be­fore the end of the year, but they won’t be do­ing it with Sanofi Gen­zyme as a part­ner.

The Cam­bridge, MA-based biotech says that Sanofi Gen­zyme opt­ed not to pick up the op­tion out­lined in their $845 mil­lion deal, ev­i­dent­ly be­cause it didn’t in­clude US rights.

Voy­ager’s shares drop 19% in af­ter-mar­ket trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.